Growth • Novo Nordisk
NVO
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
18,9%
CAGR Revenue 5Y
Revenue Compound Annual Growth Rate in the last 5 years.
19,6%
CAGR Op. Income 5Y
Operating Income Compound Annual Growth Rate in the last 5 years.
21%
CAGR Net Income 5Y
Net Income Compound Annual Growth Rate in the last 5 years.
22,5%
CAGR EPS 5Y
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
21,1%
CAGR Normalized EPS 5Y
Normalized Earnings Per Share Compound Annual Growth Rate in the last 5 years.
20,9%
CAGR OCF 5Y
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!